Compare · NCEL vs NVO
NCEL vs NVO
Side-by-side comparison of NewcelX Ltd. (NCEL) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NCEL and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 10549.4x NCEL ($16.5M).
- Over the past year, NCEL is down 82.8% and NVO is down 30.4% - NVO leads by 52.4 points.
- NVO has been more active in the news (3 items in the past 4 weeks vs 1 for NCEL).
- NVO has more recent analyst coverage (25 ratings vs 0 for NCEL).
- Company
- NewcelX Ltd.
- Novo Nordisk A/S
- Price
- $2.84-5.33%
- $38.82-1.05%
- Market cap
- $16.5M
- $173.66B
- 1M return
- -10.69%
- -10.14%
- 1Y return
- -82.79%
- -30.36%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 1
- 3
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NCEL
- NewCelX Management to Attend Breakthrough T1D Congress in Philadelphia, Advancing Its Mission to Develop a Cure for Type 1 Diabetes
- SEC Form EFFECT filed by NewcelX Ltd.
- SEC Form POS AM filed by NewcelX Ltd.
- SEC Form 6-K filed by NewcelX Ltd.
- SEC Form EFFECT filed by NewcelX Ltd.
- SEC Form D filed by NewcelX Ltd.
- SEC Form F-3 filed by NewcelX Ltd.
- SEC Form 6-K filed by NewcelX Ltd.
- SEC Form 6-K filed by NewcelX Ltd.
- NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank